FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, enantiomers or stereoisomers; in which values for groups W1, W2, R3, L, Z, a, b, m, c, d, etc. are defined in patent claim.
EFFECT: invention also refers to pharmaceutical compositions based on said compounds possessing inhibitory activity on NF-kB, for treating inflammation or inflammatory disease, type II diabetes, insulin-resistant cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dislipidemia, retinopathy, neuropathy, macular edema, diabetic nephropathy, IgA nephropathy, CLD, inflammatory diseases of kidneys.
25 cl, 4 dwg, 25 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF FATTY ACIDS AND NIACIN AND APPLICATION THEREOF | 2010 |
|
RU2569063C2 |
| CONJUGATED LIPID DERIVATIVES | 2007 |
|
RU2480447C2 |
| NOVEL LIPID COMPOUNDS | 2007 |
|
RU2509071C2 |
| ALPHA-SUBSTITUTED OMEGA-3 LIPIDS, ACTIVATORS OR MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) | 2007 |
|
RU2507193C2 |
| STRUCTURALLY ENHANCED OXYGEN-CONTAINING FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2820995C2 |
| PANTHENOL DOCOSAHEXAENOATE AND USE THEREOF FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | 2011 |
|
RU2593203C2 |
| PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING AGE-RELATED DISEASES | 2009 |
|
RU2546108C2 |
| OMEGA-3 COMPOSITIONS, DOSAGE FORMS AND METHODS OF USING THEM | 2015 |
|
RU2741965C2 |
| USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 CONTENT | 2015 |
|
RU2705991C2 |
| BIOCIDE COMPOSITIONS | 2014 |
|
RU2654110C2 |
